Vorinostat
- CAS No.
- 149647-78-9
- Chemical Name:
- Vorinostat
- Synonyms
- Suberoylanilide hydroxamic acid;N1-hydroxy-N8-phenyloctanediaMide;SAHA cpd;Vornostat;vorinosta;Vorinostat (SAHA, MK0683);suberoylaMide hydroxaMic acid;MK0683;CS-1949;FuLi, he
- CBNumber:
- CB3506806
- Molecular Formula:
- C14H20N2O3
- Molecular Weight:
- 264.32
- MOL File:
- 149647-78-9.mol
- MSDS File:
- SDS
- Modify Date:
- 2024/11/17 8:48:38
| Melting point | 161-162°C |
|---|---|
| Density | 1.2 |
| RTECS | RG8835000 |
| storage temp. | -20°C |
| solubility | DMSO: ≥15mg/mL |
| form | powder |
| pka | 9.48±0.20(Predicted) |
| color | white to tan |
| Merck | 14,10034 |
| Stability | Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 6 months. |
| InChIKey | WAEXFXRVDQXREF-UHFFFAOYSA-N |
| CAS DataBase Reference | 149647-78-9(CAS DataBase Reference) |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS08 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Danger | |||||||||
| Hazard statements | H341-H360 | |||||||||
| Precautionary statements | P201-P308+P313 | |||||||||
| Hazard Codes | T | |||||||||
| Risk Statements | 61-68 | |||||||||
| Safety Statements | 53-36/37-45 | |||||||||
| WGK Germany | 3 | |||||||||
| HS Code | 29280000 | |||||||||
| NFPA 704 |
|
Vorinostat price More Price(3)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich(India) | SML0061 | SAHA ≥98% (HPLC) | 149647-78-9 | 5MG | ₹10110.55 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | SML0061 | SAHA ≥98% (HPLC) | 149647-78-9 | 25MG | ₹40983.45 | 2022-06-14 | Buy |
| TCI Chemicals (India) | H1388 | N-Hydroxy-N'-phenyloctanediamide | 149647-78-9 | 200MG | ₹14500 | 2022-05-26 | Buy |
Vorinostat Chemical Properties,Uses,Production
Description
Vorinostat is the first drug in a new class of anti-cancer agents that inhibit histone deacetylases (HDAC). It was launched as an oral treatment for cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent, or recurrent disease on or following two systemic therapies. HDACs are enzymes that catalyze the removal of the acetyl modification on lysine residues of proteins, including the core nucleosomal histones. Together with their counterpart histone acetyltransferases (HATs), HDACs regulate the acetylation level of the histones, which plays an important role in the regulation of chromatin plasticity and gene transcription. Hypoacetylation of histones is associated with a condensed chromatin structure resulting in the repression of gene transcription, whereas acetylated histones are associated with a more open chromatin structure and activation of transcription. In some cancer cells, there is an overexpression of HDACs, resulting in hypoacetylation of histones. Inhibitors of HDAC are thought to transcriptionally reactivate dormant tumor-suppressor genes by allowing for the accumulation of acetyl groups on histones and an open chromatin structure. Vorinostat inhibits the enzymatic activity of HDAC1, HDAC2, HDAC3, and HDAC6 at nanomolar concentrations (IC50 ＜86 nM). In vitro, it induces growth arrest, differentiation or apoptosis in a variety of tumor cells. In addition, vorinostat inhibits tumor growth in animal models bearing solid tumors, including breast, prostate, lung and gastric cancers, as well as hematologic malignancies such as multiple myeloma and leukemias.
Chemical Properties
White Crystalline Solid
Uses
Vorinostat, a histone deacetylase (HDAC) inhibitor from Merck, was approved for the treatment of cutaneous T-cell lymphoma (CTCL), a type of non-Hodgkin’s lymphoma. Vorinostat was shown to inhibit HDAC1, HDAC2, HDAC3 and HDAC6 at nanomolar concentrations. HDAC inhibitors are potent differentiating agents toward a variety of neoplasms, including leukemia and breast and prostate cancers.
Definition
ChEBI: A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
General Description
Histones are proteins around which DNA is wound in the process of packing DNA into the nucleus. They also havea role in regulating the transcription of genes, and this iscontrolled by the covalent modifications acetylation, phosphorylation,and methylation to which they are subject.
Vorinostat fits the basic pharmacophore for the HDACis, which consists of a hydrophobic cap regionconnected to a zinc coordinating functionality by a hydrophobiclinker.The hydroxamic acid functionality iscapable of bidendate binding to zinc present in the enzymeand is a major factor in the overall binding of the compound.The compound inhibits HDAC1, 2, 3, and 6 classes of thisenzyme with nanomolar (＜86 nM) IC50 values.
The agent is given orally and is available in 100-mg capsulesfor the treatment of cutaneous T-cell lymphoma. Thebioavailability is 43%, and the agent is 71% bound toplasma proteins. Extensive metabolism of the agent occursto give the O-glucuronide of the hydroxamic acid functionand 4-anilino-4-oxobutanoic acid with minimal involvementof isozymes of CYP. The metabolites, both of whichare inactive, are eliminated in the urine and the drug has aterminal elimination half-life of 2 hours. The most commonlyreported adverse effects are fatigue, diarrhea, andnausea.
Vorinostat Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| Alfa Omega Pharma | +91-8050045945 +91-9972665399 | Maharashtra, India | 126 | 58 | Inquiry |
| Hetero Drugs Limited | +91-4023704923 +91-4023704923 | Telangana, India | 296 | 58 | Inquiry |
| Rivashaa Agrotech Biopharma Pvt. Ltd. | +91-26463395 +91-7926462688 | Gujarat, India | 1615 | 58 | Inquiry |
| Manus Aktteva Biopharma LLP | 08048250218Ext 800 | Ahmedabad, India | 655 | 58 | Inquiry |
| Sai Prathyu Marketing | 91-9666672409 | Hyderabad, India | 162 | 58 | Inquiry |
| Alfa-Omega Pharma | 08080929094 | Karnataka, India | 73 | 58 | Inquiry |
| Manus Aktteva | +91 (79) 6512-3395 | New Delhi, India | 581 | 34 | Inquiry |
| Pharmaffiliates Analytics and Synthetics P. Ltd | +91-172-5066494 | Haryana, India | 6739 | 58 | Inquiry |
| SynZeal Research Pvt Ltd | +1 226-802-2078 | Gujarat, India | 6514 | 58 | Inquiry |
| New Rise Life Science | 91-8790905328 | Hyderabad, India | 150 | 58 | Inquiry |
149647-78-9(Vorinostat)Related Search:
1of4
chevron_right